CORONA REMEDIES
|
|
| BOM : 544644     NSE : CORONA     | |
| LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Upward Pledged Shares : None or < 25% |
Jun 24,2026 |
|
Price(EOD): ₹ 1,949.00
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 11,927.88 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| CORONA REMEDIES | 6.8% | 13.8% | NA |
| SUN PHARMACEUTICAL INDUSTRIES | 2.6% | 1.2% | 13% |
| DIVIS LABORATORIES | 1.3% | -2.1% | 3.8% |
| TORRENT PHARMACEUTICALS | 1.5% | 0.7% | 37.1% |
| CIPLA | 6.1% | 2.4% | -5.9% |
| DR REDDYS LABORATORIES | 2.6% | -0.4% | -2.1% |
| MANKIND PHARMA | 7% | 2% | 7.9% |
| LUPIN | 4% | 3.4% | 20.4% |
| ZYDUS LIFESCIENCES | 4.8% | 7% | 13.1% |
FUNDAMENTAL ANALYSIS OF CORONA REMEDIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF CORONA REMEDIES
 | Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
70.2
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 169.79 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] 15.96
P/B Calculated based on Book Value of Rs 746.86 Cr
[Latest Year - Mar2026 - Consolidated Results ] 8.83
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,350.33 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
16833% 13472% - |
SHARE PRICE MOMENTUM OF CORONA REMEDIES
CORONA REMEDIES vs SENSEX
DEBT OF CORONA REMEDIES
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2026 2025 2024 Avg_3yrs |
0.19 0.1 0.28 0.19 |
0.19 0.1 0.28 0.19 |
|
[Last Annual Data : Mar2026]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF CORONA REMEDIES
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2026 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF CORONA REMEDIES
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
3.12% -25.42% -1.32% 9.21% |
18.61% -10.66% -6.27% 0.63% |
| QtrlyTrend |
0 | |
| Latest Qtr: Mar2026 | ||
| Quarterly Result Analysis → | ||
CORONA REMEDIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 3.3% | 2.8% | 12% |
| BSE IPO | 2.7% | 9.9% | 18.9% |
| BSE 1000 | 0.2% | 2.5% | 0.6% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY IPO INDEX | 2.4% | 9.7% | 13.8% |
| NIFTY MICROCAP 250 | 1.3% | 8% | 6.1% |
| NIFTY TOTAL MARKET | 0.1% | 2.3% | 0.9% |
You may also like the below Video Courses
FAQ about CORONA REMEDIES
Is CORONA REMEDIES good for long term investment?
As on Jun 24,2026, the Fundamentals of CORONA REMEDIES look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of CORONA REMEDIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is CORONA REMEDIES UnderValued or OverValued?
As on Jun 24,2026, CORONA REMEDIES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of CORONA REMEDIES ?
As on Jun 24,2026, the Intrinsic Value of CORONA REMEDIES is Rs. 12.93 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 11.51
Fair Value [Median EV / Sales Model] : Rs. 14.36
Fair Value [Median Price / Sales Model] : Rs. 0.00
Estimated Median Fair Value of CORONA REMEDIES : Rs. 12.93
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.